Peritoneal Dialysis Mechanisms and Clinical Outcomes

Peritoneal dialysis exploits the peritoneal membrane as a semi-permeable barrier to remove waste solutes and excess fluid in patients with renal failure. Dialysate instilled into the peritoneal cavity creates an osmotic gradient that drives ultrafiltration across the mesothelial layer and underlying capillaries. Solute clearance occurs by diffusion and convection through intercellular junctions and capillary walls, with transport characteristics defined by membrane vascularity and tissue thickness. Repeated exposure to bioincompatible solutions, episodes of peritonitis and mechanical stress induce structural alterations characterised by fibrosis, angiogenesis and loss of mesothelial integrity. Progressive membrane dysfunction manifests clinically as ultrafiltration failure, declining solute removal and technique discontinuation. Membrane transport status, stratified by small-solute equilibration, informs dwell times and prescription: high-transporters achieve rapid exchange but risk net fluid loss, whereas low-transporters require longer dwells. Maintaining fluid balance, minimising protein loss and preserving residual renal function are central to favourable clinical outcomes. Long-term complications include peritoneal fibrosis, encapsulating peritoneal sclerosis and increased cardiovascular risk. Advances in solution biocompatibility, transport profiling and non-invasive biomarkers have enhanced patient survival and quality of life, yet preserving membrane function remains a global challenge. Integration of metabolic, immunological and vascular insights is shaping personalised strategies to prolong technique longevity and reduce morbidity.

Research from Nature Portfolio

Recent studies have demonstrated that targeting metabolic and paracrine pathways can protect the peritoneal membrane from fibrotic remodelling. One investigation showed that activation of AMP-activated protein kinase by metformin in mesothelial cells mitigates epithelial-to-mesenchymal transition, decreases oxidative stress and preserves membrane architecture and ultrafiltration capacity in experimental dialysis models. Another study revealed that blockade of connective tissue growth factor inhibits fibroblast proliferation, myofibroblast accumulation and angiogenesis, thereby attenuating fibrotic thickening and restoring peritoneal function. These findings highlight metabolic modulation and growth factor inhibition as promising strategies to counteract peritoneal injury.

Peritoneal Dialysis Mechanisms and Clinical Outcomes publication trend

The graph below shows the total number of articles in peritoneal dialysis mechanisms and clinical outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Peritoneal membrane: The serous lining of the abdominal cavity acting as a semi-permeable barrier in dialysis.

Mesothelial cells: A monolayer of specialised epithelial cells covering the peritoneal membrane.

Ultrafiltration: Fluid removal driven by osmotic or hydrostatic pressure differences across a membrane.

Solute clearance: The process by which waste molecules move from blood into dialysate by diffusion and convection.

Fibrosis: Excess deposition of extracellular matrix proteins leading to tissue stiffening and dysfunction.

Epithelial-to-mesenchymal transition (EMT): A process whereby epithelial cells acquire migratory and fibrogenic characteristics.

Autophagy: Intracellular degradation of damaged organelles and proteins that can influence cell survival and phenotype.

Reactive oxygen species (ROS): Highly reactive molecules containing oxygen that can trigger cellular damage and signalling pathways.

References

1. Restoration of CPT1A-mediated fatty acid oxidation in mesothelial cells protects against peritoneal fibrosis. Theranostics (2023).
2. Autophagy caused by oxidative stress promotes TGF-β1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells. Cell Death & Disease (2024).
3. Hyperglycolysis in endothelial cells drives endothelial injury and microvascular alterations in peritoneal dialysis. Clinical and Translational Medicine (2023).
4. Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress. Scientific Reports (2017).
5. Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis. Scientific Reports (2017).